purpos
chronic
graftversushost
diseas
cgvhd
sever
immunolog
complic
occur
allogen
hematopoiet
stem
cell
transplant
hsct
although
oral
cgvhd
occur
cgvhd
patient
lead
decreas
qualiti
life
etiolog
poorli
understood
present
retrospect
crosssect
analysi
oral
cgvhd
patient
sought
test
feasibl
liquid
chromatographi
tandem
mass
spectrometri
lcmsm
identifi
protein
biomark
oral
cgvhd
gain
clearer
understand
salivari
protein
impact
oral
cgvhd
method
use
unstimul
whole
saliva
compar
pool
saliva
five
patient
diagnosi
moder
sever
oral
cgvhd
genderand
agematch
pool
five
cgvhd
patient
oral
mucos
find
lcmsm
use
identifi
salivari
protein
follow
ingenu
pathway
analysi
ipa
select
mass
spectrometr
find
includ
lactotransferrin
lactoperoxidas
albumin
confirm
target
labelfre
quantif
result
lcmsm
led
confid
identif
protein
protein
chang
abund
least
fold
includ
protein
identifi
oral
cgvhd
group
downregul
fold
confirm
lactotransferrin
lactoperoxidas
oral
cgvhd
saliva
use
target
labelfre
quantif
ipa
analysi
implic
pathway
involv
cellular
metabol
immunoregul
conclus
reduct
salivari
lactoperoxidas
lactotransferrin
sever
cystein
proteinas
inhibitor
famili
protein
suggest
impair
oral
antimicrobi
host
immun
cgvhd
patient
shotgun
proteom
analysi
oral
cgvhd
saliva
use
target
labelfre
quantif
select
protein
support
use
mass
spectrometri
futur
valid
larg
patient
popul
noninvas
test
screen
earli
detect
monitor
cgvhd
chronic
graftversushost
diseas
cgvhd
sever
immunolog
complic
occur
allogen
hematopoiet
stem
cell
transplant
hsct
lead
caus
late
nonrelaps
death
patient
group
gvhd
debilit
sequela
barrier
limit
widespread
use
hsct
chronic
gvhd
affect
nearli
everi
organ
system
donororigin
cellular
respons
direct
host
tissu
lead
immun
dysregul
immunodefici
impair
organ
function
end
organ
effect
cgvhd
often
resembl
autoimmun
immunolog
disord
suggest
common
pathophysiolog
direct
caus
decreas
patient
qualiti
life
impair
physic
statu
earli
mortal
oral
manifest
present
least
patient
cgvhd
oral
caviti
highli
affect
organ
system
cgvhd
second
skin
involv
spectrum
oral
cgvhd
includ
mucos
lesion
salivari
gland
dysfunct
restrict
mouth
open
lead
pain
xerostomia
loss
oral
function
current
diagnosi
base
clinic
exam
conjunct
histopatholog
featur
regardless
etiolog
chang
salivari
function
composit
saliva
affect
oral
homeostasi
lead
dental
periodont
oral
mucos
diseas
whole
saliva
oral
fluid
complex
mixtur
salivari
gland
secret
gingiv
crevicular
fluid
plasma
protein
transud
oral
keratinocyt
product
microbi
flora
serv
myriad
protect
antimicrobi
immunomodulatori
antiinflammatori
function
chang
salivari
function
mucos
breakdown
seen
cgvhd
could
alter
salivari
composit
directli
influenc
oral
manifest
includ
pain
dysfunct
avoid
nutrit
food
infect
oral
health
mucos
damag
seen
oral
cgvhd
would
disrupt
local
oral
environ
facilit
entri
microbi
pathogen
system
circul
patient
potenti
contribut
sepsi
hsct
cgvhd
often
mimic
find
autoimmun
disord
consider
autoimmun
diseas
known
affect
salivari
gland
andor
oral
mucosa
syndrom
scleroderma
system
lupu
erythematosu
may
provid
insight
pathophysiolog
organ
involv
cgvhd
oral
caviti
proteom
analysi
saliva
shown
great
promis
tool
identif
biomark
primari
syndrom
saliva
could
reflect
local
oral
consequ
system
process
cgvhd
could
help
elucid
underli
pathophysiolog
diseas
process
longitudin
studi
imanguli
et
al
first
report
chang
salivari
proteom
earli
posthsct
period
month
persist
though
month
posthsct
consider
advanc
detect
identif
salivari
proteom
past
sever
year
enabl
finer
analysi
content
saliva
detail
connect
system
pathway
consequ
aim
present
studi
twofold
first
identifi
protein
marker
oral
cgvhd
could
lead
improv
diagnosi
monitor
therapeut
intervent
current
diagnost
gold
standard
oral
cgvhd
clinic
exam
pair
biopsi
buccal
mucosa
given
serial
mucos
biopsi
recommend
monitor
oral
caviti
would
prefer
standpoint
patient
practition
identifi
salivari
marker
noninvas
serial
test
second
clearer
understand
salivari
protein
impact
oral
cgvhd
elicit
inform
mechan
etiolog
process
oral
cgvhd
turn
could
lead
develop
specif
therapi
retrospect
crosssect
pilot
studi
compar
whole
saliva
patient
diagnosi
moder
sever
oral
cgvhd
measur
use
oral
mucos
rate
scale
orm
genderand
agematch
control
group
cgvhd
patient
oral
mucos
find
liquid
chromatographi
tandem
mass
spectrometri
lcmsm
led
confid
identif
protein
protein
chang
abund
least
fold
includ
protein
identifi
oral
cgvhd
group
select
mass
spectrometr
find
includ
lactotransferrin
lactoperoxidas
albumin
confirm
target
labelfre
quantif
patient
studi
enrol
subject
ongo
transplant
cgvhd
studi
nation
institut
health
nation
cancer
institut
nci
clinicaltrialsgov
data
involv
human
subject
compli
guid
principl
experiment
procedur
found
declar
helsinki
world
medic
associ
subject
sign
nci
institut
review
board
approv
inform
consent
patient
underw
allogen
hsct
clinic
diagnosi
cgvhd
organ
system
refer
nih
dental
clinic
comprehens
evalu
oral
caviti
referr
studi
group
five
male
patient
select
describ
patient
diagnos
oral
cgvhd
oral
cgvhd
compar
gender
agematch
male
patient
diagnos
oral
cgvhd
oral
cgvhd
male
chosen
pilot
studi
identifi
bonafid
chang
cgvhd
patient
control
gvhd
patient
sex
hormon
relat
puberti
menstrual
cycl
report
alter
abund
protein
femal
subject
patient
refer
nih
dental
clinic
cgvhd
undergo
detail
examin
dentist
expertis
oral
cgvhd
use
orm
scale
rate
scale
total
score
rang
design
evalu
oral
mucos
chang
hsct
treatment
orm
score
consid
moder
sever
oral
cgvhd
studi
case
punch
biopsi
right
buccal
mucosa
taken
sent
patholog
histopatholog
review
possibl
oral
cgvhd
find
formalin
fix
paraffin
embed
section
hematoxylin
eosin
stain
statist
analysi
characterist
studi
group
perform
use
mannwhitney
test
determin
differ
two
group
continu
variabl
consid
statist
signific
whole
unstimul
saliva
sampl
collect
ice
steril
tube
time
oral
evalu
immedi
collect
volum
proteas
cocktail
inhibitor
ad
saliva
frozen
perform
mass
spectrometri
analysi
saliva
sampl
thaw
centrifug
x
g
min
separ
supernat
pellet
subsequ
protein
concentr
determin
bicinchonin
acid
bca
aliquot
prepar
pool
equal
amount
protein
subject
within
group
pool
normal
differ
subject
reduc
individu
variat
mass
spectrometri
ms
remain
saliva
sampl
subsequ
store
analysi
fifti
microgram
pool
whole
saliva
group
oral
gvhd
oral
gvhd
precipit
overnight
trichloroacet
acid
tca
protein
pellet
dissolv
denatur
urea
reduc
mm
diothiothretol
min
room
temperatur
follow
alkyl
mm
iodoacetamid
room
temperatur
dark
min
urea
concentr
dilut
ammonium
bicarbon
prior
digest
trypsin
promega
madison
wi
overnight
gentl
shake
proteintotrypsin
ratio
ww
peptid
desalt
use
oasi
mg
revers
phase
cartridg
water
milford
vacuum
concentr
dryness
subsequ
digest
divid
two
aliquot
one
aliquot
use
peptideprotein
identif
rel
protein
quantif
spectral
count
second
aliquot
labelfre
target
quantif
select
differenti
express
protein
five
microgram
tryptic
peptid
mixtur
oral
cgvhd
oral
cgvhd
subject
load
separ
onto
zorbax
c
trap
column
agil
tech
santa
clara
ca
min
flow
rate
desalt
peptid
mixtur
peptid
separ
cm
picofrit
biobas
c
analyt
column
new
object
woburn
use
onlin
eksig
dublin
ca
nanolc
ultra
hplc
system
peptid
elut
use
min
acetonitril
gradient
flow
rate
nlmin
peptid
ioniz
use
electrospray
ioniz
esi
posit
ion
mode
detect
ltqorbitrap
velo
thermo
fisher
scientif
san
jose
ca
precursor
ion
select
msm
use
datadepend
method
top
intens
ion
precursor
scan
select
precursor
ion
measur
orbitrap
resolut
set
mz
precursor
ion
fragment
collisioninduc
dissoci
cid
normal
collis
energi
fragment
ion
measur
ltq
target
lcmsm
run
h
discoveri
run
h
lcmsm
data
search
use
mascot
algorithm
within
proteom
discover
thermo
electron
corp
san
jose
ca
human
swissprot
protein
databas
version
obtain
peptid
protein
identif
search
trypsin
specifi
enzym
protein
cleavag
allow
miss
cleavag
oxid
carbamidomethyl
c
set
dynam
fix
modif
mass
toler
ppm
da
set
precursor
fragment
ion
respect
data
set
contain
downregul
protein
analyz
ingenu
pathway
analysi
version
system
wwwingenuitycom
mountain
view
ca
statist
signific
protein
identif
ipa
base
map
input
protein
continu
curat
databas
publish
literatur
rang
function
cellular
locat
canon
pathway
diseas
interrelationship
associ
protein
dataset
canon
pathway
ingenu
pathway
knowledg
base
measur
ratio
number
molecul
data
map
pathway
divid
total
number
molecul
map
canon
pathway
righttail
fisher
exact
test
use
calcul
pvalu
probabl
associ
protein
dataset
canon
pathway
random
pathway
p
valu
least
associ
protein
select
potenti
pathway
affect
oral
cgvhd
target
analysi
nanolc
paramet
lcmsm
howev
ms
paramet
adjust
target
specif
set
peptid
inclus
list
prepar
consist
accur
mz
valu
tryptic
peptid
select
group
differenti
express
protein
confirm
differenti
express
observ
lcm
peptid
select
inclus
list
base
criteria
tryptic
peptid
select
contain
miss
cleavag
charg
state
contain
methionin
residu
five
peptid
inject
ms
precursor
detect
orbitrap
resolut
mz
fragment
ion
measur
ltq
precursor
mz
inclus
list
detect
scan
subsequ
msm
spectrum
acquir
order
account
potenti
coelut
peptid
subsequ
msm
scan
event
includ
method
confirm
peptid
autom
labelfre
quantif
carri
use
inhous
develop
softwar
quoil
msm
data
visual
mascot
result
import
scaffold
proteom
softwar
portland
tabl
summar
clinic
oral
cgvhd
characterist
studi
group
group
includ
similarli
age
male
major
match
unrel
peripher
blood
hsct
evalu
oral
cgvhd
least
day
transplant
system
immunosuppress
score
accord
intens
immunosuppress
scale
use
classif
level
system
immunosuppress
posttranspl
studi
mild
singl
agent
prednison
mgkgday
mgkgday
andor
singl
agentmod
mgkgday
importantli
differ
mean
system
immunosuppress
oral
cgvhd
oral
cgvhd
subject
studi
also
signific
differ
salivari
flow
rate
group
oral
cgvhd
mlmin
oral
gvhd
pvalu
oral
cgvhd
group
orm
score
oral
cgvhd
group
low
orm
score
versu
figur
show
patient
oral
cgvhd
group
highlight
clinic
histolog
find
seen
oral
cgvhd
right
panel
compar
patient
oral
cgvhd
group
left
panel
oral
cgvhd
patient
present
clinic
intraor
atrophi
erythema
hyperkeratosi
lichenoid
reaction
ulcer
edema
histolog
copiou
lymphocyt
infiltr
presenc
apoptot
bodi
oral
buccal
mucosa
quantit
proteom
studi
perform
identifi
chang
abund
protein
oral
gvhd
oral
cgvhd
group
figur
show
work
flow
schemat
identif
confirm
differenti
express
protein
equal
amount
protein
pool
subject
within
group
pool
identif
mass
spectrometri
subsequ
target
labelfre
quantit
signific
differ
note
mean
total
protein
per
ml
individu
sampl
either
group
oral
cgvhd
oral
cgvhd
protein
deem
confid
match
least
two
uniqu
peptid
detect
given
protein
result
identif
protein
fold
chang
cutoff
appli
list
lead
identif
differenti
express
protein
includ
protein
identifi
oral
cgvhd
group
differenti
express
protein
list
supplementari
tabl
spectral
count
sever
protein
rel
high
eg
indic
identifi
differ
real
part
instrument
issu
note
sever
member
cystein
proteinas
inhibitor
famili
identifi
studi
cystatinsa
cystatinc
cystatinb
cystatin
cystatind
downregul
oral
cgvhd
cystatinsn
chang
abund
differenti
express
protein
found
oral
cgvhd
oral
cgvhd
whole
saliva
protein
identifi
oral
cgvhd
group
protein
downregul
oral
cgvhd
compar
oral
cgvhd
group
among
downregul
protein
chang
fold
n
chang
fold
protein
chang
fold
chang
fold
contrast
protein
show
littl
chang
abund
base
fold
ratio
chang
cutoff
shown
fig
differenti
express
protein
downregul
map
use
ingenu
pathway
analys
ipa
softwar
version
determin
statist
signific
p
canon
pathway
base
publish
literatur
date
oral
cgvhd
group
protein
map
differ
pathway
fig
among
differ
pathway
glycolysi
largest
number
involv
protein
four
pathway
involv
three
protein
protein
detect
littl
chang
abund
protein
detect
either
identifi
oral
cgvhd
group
downregul
downregul
protein
protein
antimicrobi
activ
chosen
confirm
target
labelfre
approach
lactotransferrin
lactoperoxidas
serum
albumin
chang
significantli
includ
intern
control
confirm
lactotransferrin
lactoperoxidas
target
labelfre
approach
shown
fig
protein
two
differ
peptid
use
confirm
deem
confid
peptid
show
similar
differenti
express
figur
show
chromatogram
one
two
peptid
lactotransferrin
nllfndnteclar
lactoperoxidas
vgpllacllgk
quantif
three
protein
oral
cgvhd
oral
cgvhd
sampl
analyz
fold
chang
valu
singl
precursor
ion
chromatogram
lactotransferrin
lactoperoxidas
abund
peptid
calcul
height
peak
intens
shown
yaxi
xaxi
show
time
peptid
elut
retent
time
three
peptid
compar
indic
littl
variat
peptid
elut
oral
cgvhd
oral
cgvhd
experiment
run
top
chromatogram
fig
panel
b
repres
oral
cgvhd
bottom
panel
b
oral
cgvhd
chromatogram
stark
differ
peptid
abund
lactotransferrin
lactoperoxidas
fig
b
respect
shown
fold
chang
case
albumin
show
chang
abund
salivari
proteom
technolog
emerg
scienc
whose
advanc
drive
field
salivari
diagnost
identifi
understand
diseas
process
current
pilot
studi
appli
cuttingedg
salivari
proteom
techniqu
identif
protein
pool
saliva
ageand
gendermatch
cgvhd
patient
without
oral
cgvhd
overarch
goal
determin
potenti
techniqu
gvhd
saliva
analysi
studi
total
protein
confid
identifi
amongst
protein
hemoglobin
subunit
alpha
hemoglobin
subunit
beta
identifi
may
due
contamin
saliva
sampl
hemolysi
red
blood
cell
alpha
beta
hemoglobin
subunit
also
detect
whole
ductal
saliva
collect
directli
cannul
parotid
gland
strongli
suggest
subunit
hemoglobin
may
intrins
part
saliva
postul
blood
protein
may
enter
normal
saliva
leaki
epithelium
parotid
potenti
salivari
gland
detect
level
differ
group
studi
blood
contamin
cgvhd
saliva
consid
major
confound
factor
fold
chang
cutoff
appli
list
result
identif
differenti
express
protein
twofold
cutoff
differenti
express
protein
indic
doubl
increas
express
ratio
ingenu
pathway
analysi
ipa
analysi
perform
differenti
express
protein
lead
identif
canon
pathway
involv
oral
cgvhd
popul
compar
oral
cgvhd
control
target
free
label
confirm
focus
protein
lactotransferrin
lactoperoxidas
albumin
detect
signific
downregul
lactotransferrin
lactoperoxidas
chang
albumin
level
saliva
gvhd
subject
among
identifi
pathway
major
protein
relat
cellular
metabol
glycolysisgluconeogenesi
inositol
glutathion
pyruv
argnin
prolin
metabol
immun
signal
primari
immunodefici
signal
although
pathway
analysi
use
ipa
protein
provid
stringent
evid
direct
associ
cgvhd
pathophysiolog
may
provid
new
insight
potenti
import
network
indepth
mechanist
analysi
valid
involv
diseas
pathogenesi
clinic
present
oral
cgvhd
includ
atrophi
erythema
hyperkeratosi
lichenoid
reaction
ulcer
edema
seen
lower
lip
e
maxillari
anterior
gingiva
f
buccal
mucosa
g
patient
oral
cgvhd
compar
normal
intraor
mucosa
patient
oral
cgvhd
ac
h
e
stain
oral
mucosa
abovematch
patient
demonstr
characterist
gvhdlike
chang
buccal
mucosa
compar
oral
cgvhd
tissu
includ
preval
lymphocyt
infiltr
apoptot
bodi
h
buccal
biopsi
section
shown
similar
orient
magnif
identif
quantif
fig
insolut
trypsin
digest
confirm
fig
oral
cgvhd
oral
cgvhd
lactoperoxidas
one
two
protein
present
lower
amount
gvhd
saliva
confirm
part
ipaidentifi
phenylanin
metabol
pathway
lactoperoxidas
catalyz
oxid
certain
intermedi
within
phenyalanin
pathway
howev
lactoperoxidas
also
natur
antimicrobi
compound
found
mammalian
saliva
mucu
milk
natur
acceptor
molecul
lactoperoxidas
bodi
thiocyan
whose
oxid
product
hypothiocyan
potent
antibacteri
compound
inhibit
growth
array
bacteria
high
concentr
lactoperoxidas
function
directli
kill
certain
bacteria
includ
escherichia
coli
pseudamona
aeruginosa
haemophilu
influenza
limit
replic
human
immunodefici
viru
particular
interest
reduct
detect
lactotransferrin
saliva
cgvhd
patient
lactotransferrin
ironbind
glycoprotein
found
high
concentr
epitheli
secret
includ
saliva
human
milk
multifunct
antimicrobi
compound
found
secondari
granul
neutrophil
also
act
primari
defens
bacteria
via
sequestr
iron
result
releas
lipopolysaccharid
lp
outer
microbi
membran
therebi
stymi
bacteri
growth
furthermor
low
level
lactotransferrin
act
synergist
antimicrobi
compound
increas
overal
potenc
rate
bacteri
kill
protein
act
antimicrobi
compound
also
mitogen
capac
play
role
activ
cellular
immun
system
independ
macrophag
activ
lactotransferrin
involv
previous
implic
oral
gut
cgvhd
case
report
detail
success
use
supplement
lactoferrin
treat
gut
gvhd
refractori
convent
immunosuppress
therapi
saliva
survey
group
found
increas
salivari
level
lactotransferrin
posttranspl
gvhd
patient
contrast
present
studi
includ
posttranspl
agematch
patient
popul
much
later
averag
involv
screen
howev
clearli
implic
lactotransferrin
alter
salivari
proteom
follow
hsct
sever
member
cystein
proteinas
inhibitor
famili
identifi
studi
cystatinsa
cystatinc
cystatinb
cystatin
cystatind
downregul
oral
cgvhd
cystatinsn
chang
abund
protein
secret
extracellularli
inhibit
proteinas
therebi
limit
proteolysi
tissu
damag
cystatin
potent
inhibitor
human
coronaviru
physiolog
salivari
concentr
thu
lower
level
protein
may
lead
increas
tissu
damag
lower
defens
common
viral
infect
taken
togeth
reduct
lactoperoxidas
lactotransferrin
sever
cystein
proteinas
inhibitor
famili
protein
suggest
impair
oral
antimicrobi
host
immun
cgvhd
patient
xerostomia
report
oral
cgvhd
patient
statist
differ
mean
salivari
flow
rate
group
studi
howev
flow
rate
group
slightli
report
unstimul
flow
rate
healthi
individu
mlmin
concord
clinic
experi
patient
group
suscept
frequent
oral
infect
irrit
though
publish
data
compar
rate
oral
infect
fungal
viral
bacteri
posthsct
patient
respect
cgvhd
statu
previou
salivari
analys
cgvhd
patient
report
differenti
express
ion
protein
use
assort
method
flame
photometri
spectrophotometri
atom
absorpt
differenti
gel
electrophoresi
show
peptid
elut
plot
inten
lactotransferrin
b
lactoperoxidas
oral
cgvhd
classif
illustr
downregul
protein
oral
cgvhd
group
dige
techniqu
follow
identif
protein
mass
spectrometri
although
effect
tool
limit
includ
restrict
dynam
rang
poor
identif
membran
protein
poor
reproduc
overcom
limit
insolut
digest
protein
util
studi
molecul
identifi
use
liquid
chromatographi
coupl
tandem
mass
spectrometri
lcmsm
date
confirm
potenti
salivari
marker
cgvhd
proteom
studi
perform
use
western
blot
elisa
techniqu
give
valuabl
result
howev
limit
avail
sensit
specif
antibodi
protein
thu
often
critic
use
nonantibodi
base
method
multipl
reaction
monitor
mrm
accur
inclus
mass
screen
aim
studi
use
target
labelfre
confirm
three
potenti
marker
lactotransferrin
lactoperoxidas
albumin
success
develop
quantit
assay
collect
first
shotgun
proteom
analysi
cgvhd
subject
use
mass
spectrometri
control
gender
age
intens
immunosuppress
studi
confid
identifi
protein
differenti
express
includ
protein
uniqu
express
oral
cgvhd
group
formal
valid
specif
find
requir
larger
studi
addit
inform
gain
longitudin
sampl
target
labelfre
quantif
select
protein
support
use
mass
spectrometri
valid
larg
patient
popul
noninvas
test
screen
earli
detect
monitor
cgvhd
patient
oral
cgvhd
lower
innat
salivari
defens
oral
microbi
viral
insult
call
greater
clinic
dilig
maintain
oral
system
health
patient
oral
cgvhd
